Dabrafenib and/or Trametinib Rollover Study

Summary

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.

Eligibility

Inclusion Criteria:

* Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective.
* In the opinion of the Investigator would benefit from continued treatment.

Exclusion Criteria:

* Patient has been previously permanently discontinued from study treatment in the parent protocol.
* Patient's indication is commercially available and reimbursed in the local country.
* Patient currently has unresolved toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study.

Conditions7

Interventions2

Locations5 sites

Find trials near these locations

Related trials

• A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer — Tianjin Medical University Cancer Institute and Hospital
• A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. — Centre Leon Berard
• Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma — Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
• ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Melanoma Metastasized to the Brain and Steroids — Inge Marie Svane
• Precision Cancer Therapy in Rare Cancers — Oslo University Hospital
• Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion — Tianjin Medical University Second Hospital
• The Drug Rediscovery Protocol (DRUP Trial) — The Netherlands Cancer Institute

Browse More Trials